The health and wellness of ourselves and our community depend on clear, fast, and actionable information on the health threats we face as a community. Luxor Scientific offers an extensive testing menu to best serve the healthcare community. We are committed to doing our part to help inform and prepare the populace to deal with communal threats like the Flu, Monkey Pox, or COVID-19.
Infectious Disease
Detect Infection First
- Respiratory / ENT Pathogens
- SARS-CoV-2
- Sexually Transmitted Infection (STI)
- Urinary Tract Infection (UTI)
- Wound Infection
- Monkey Pox
- Tick-Borne Illnesses
- Fungal Infection
- Antibiotics (ABX) Resistance Markers
Our extensive menu ensures providers have the most comprehensive information when making treatment decisions.
- Bacterial Pathogens
- Bordetella (PAN)
- Bordetella pertussis
- Chlamydophila pneumoniae
- Haemophilus influenzae
- Klebsiella pneumoniae
- Legionella pneumophila
- Moraxella catarrhalis
- Morbillivirus Measles
- Parechovirus
- Varicella zoster virus (HHV3)
- Common Cold Pathogens
- Adenovirus 1 & 2 Alpha
- Coronavirus HKU1
- Coronavirus NL63
- Coronavirus OC43
- Coronavirus 229E
- Human Rhinovirus 1 and 2
- Fungal Pathogens
- Pneumocystis jirovecii
- Influenza Pathogens
- Influenza A virus (Pan)
- Influenza A virus H1-2009
- Influenza A virus H3
- Influenza B virus
- Parainfluenza Panel
- Parainfluenza 1
- Parainfluenza 2
- Parainfluenza 3
- Parainfluenza 4
- Respiratory Syncytial Virus
- Respiratory Syncytial Virus A
- Respiratory Syncytial Virus B
- SARS-CoV-2
- Streptococcus pyogenes (Strep A)
- Viral Pathogens
- Cytomegalovirus (HHV5)
- Enterovirus 068
- Epidemic Parotitis (Mumps)
- Epstein-Barr virus (HHV4)
- Human Bocavirus (HBoV)
- Human Herpesvirus (HHV6)
- Human Metapneumovirus
- MERS-CoV
- Mycoplasma pneumonia
- Staphylococcus aureus
- Streptococcus pneumoniae
We pride ourselves on our ability to rapidly evolve and expand to meet the needs of providers and the ever-changing US healthcare system. We were able to tangibly demonstrate this ability in January 2020 when the COVID-19 pandemic quickly spread throughout the US. During this time, many long-established labs were not prepared to accommodate the required testing needed, and additionally, the high volume of such an event. Through our scientists and their innovation, Luxor Scientific quickly developed testing for COVID-19 and swiftly pivoted to adapt our capabilities, providing not only accurate and efficient testing protocols, but very timely turnaround, among the fastest in the industry.
Our scientists were able to quickly validate COVID-19 testing using alternative sample types, including dry swab and saliva samples (to work around the national shortage of viral transport media and NP swabs, respectively). At this time, very few labs had the ability to test for COVID-19, nor the capability to test using these sample types, as they were rare in the market. Due to our innovations and quick expansion, Luxor Scientific became the first and most utilized laboratory for the South Carolina Department of Health and Environmental Control (DHEC), as well as numerous hospitals systems in South Carolina and surrounding states. At our peak of testing, we tested over 10,000 samples per day, while maintaining <24-hour turnaround time for 98% of samples (average of 14 hours from receipt in the lab).
Many STIs go undetected without having significant symptoms. Our method identifies co-infections rapidly and accurately.
Sexually transmitted infections (STIs) are on the rise nationally, many of which are asymptomatic and remain untreated. Luxor Scientific’s STI testing methods ensure highest sensitivity for detection in the industry and include testing of alternative specimen types (e.g., anal swabs and throat swabs) that are not routinely offered by many reference laboratories, but may be critical for detection based on the primary site of infection.
An STI that is particularly concerning in the United States and globally due to antibiotic resistance is Neisseria gonorrhoeae (NG). Luxor Scientific offers enhanced molecular diagnostics that distinguish among NG infections with antimicrobial resistance or reduced susceptibility from those with susceptibility to front-line antibiotics. Knowing which drugs are most likely to treat the specific NG infection is increasingly important to help guide antibiotic treatment and allow appropriate relief for a patient.
- Chlamydia trachomatis
- Haemophilus ducreyi
- Herpes simplex 1
- Herpes simplex 2
- Mycoplasma genitalium
- Mycoplasma hominis
- Neisseria gonorrhoeae
- Treponema pallidum
- Trichomonas vaginalis
- Ureaplasma urealyticum
PCR-based testing using molecular technology provides reliable and actionable results with a rapid turnaround time.
- Candida glabrata
- Candida parapsilosis
- Candida tropicalis
- Enterobacter cloacae
- Enterococcus faecalis
- Escherichia coli
- Klebsiella oxytoca
- Klebsiella pneumoniae
- Morganella morganii
- Mycoplasma hominis
- Proteus mirabilis
- Providencia stuartii
- Pseudomonas aeruginosa
- Serratia marcescens
- Staphylococcus aureus
- Staphylococcus saprophyticus
- Streptococcus agalactiae (GBS)
- Ureaplasma urealyticum
Improve your patient’s outcome with rapid pathogen detection. Culture routinely detects <2% of all known bacteria and only a subset of these microorganisms will grow within a 24-hour period. Luxor Scientific’s wound infection offerings encompass a wide range of pathogens ensuring infection is detected.
Using culture-based diagnostics, over a seven-month period, 48% of wounds healed. In contrast, using molecular testing, more than 90% of wounds healed within a similar seven-month period.1
- Acinetobacter baumannii
- Bacteroides spp.
- Citrobacter freundii & braakii
- Enterobacter aerogenes
- Enterobacter cloacae
- Enterococcus faecalis
- Enterococcus faecium
- Escherichia coli
- Klebsiella oxytoca
- Klebsiella pneumoniae
- Morganella morganii
- Proteus mirabilis
- Proteus vulgaris
- Pseudomonas aeruginosa
- Staphylococcus aureus
- Streptococcus pyogenes
With emergence of new and more resistant bacterial and viral pathogens, it remains important and relevant for laboratories to stay up to date with sensitive and specific methods of detection. Luxor Scientific can provide monkey pox testing in our Laboratory, as the CDC data shows a recent uptick in positive cases were observed in January 2023, especially in our local region and neighboring states.
- Orthopoxvirus
- Monkeypox Virus
With this change, there has been an increase in tick-borne illnesses, such as Rocky Mountain Spotted Fever (RMSF) and Lyme disease (Lyme borreliosis), that are directly linked with tick bites. At Luxor Scientific, our infectious disease serology laboratory offers specialized and rapid testing for detection of RMSF and Lyme Disease to detect antibody response to these organisms by showing either seroconversion from antibody negative to antibody positive, or by documenting a significant increase in IgG antibody titers. These serologic tests are not widely available, yet we offer 48-hour turnaround time for this testing.
- Borrelia burgdorferi Antibodies, Total
- Rickettsia rickettsii (Rocky Mountain Spotted Fever) Antibody, IgG
- Rickettsia rickettsii (Rocky Mountain Spotted Fever) Antibody, IgM
PCR analysis shortens the time to diagnosis and can unmask the presence of fastidious fungal pathogens in nails.
- Candida albicans
- Candida glabrata
- Candida krusei
- Candida tropicalis
- Trichophyton anthropophilic spp.
- Trichophyton zoophilic spp.
- Alternaria spp.
- Aspergillus spp.
- Candida parapsilosis
- Cryptococcus spp.
- Curvularia
- Epidermophyton
- Fusarium spp.
- Malassezia spp.
- Meyerozyma guilliermondii
- Microsporum canis
- Sarocladium strictum
- Scytalidium dimidiatum
- Trichosporon
Knowing which drugs are best to treat the specific infection is increasingly important to help guide antibiotic treatment and allow appropriate relief for a patient.
- Temoniera-β-lactamase (TEM)
- Sulfhydryl Variable-β-lactamase (SHV)
- Klebsiella pneumoniae carbapenemase (KPC)
- CefoTaXime-M-β-lactamase (CTXM 1)
- CefoTaXime-M-β-lactamase (CTXM 2)
- CefoTaXime-M-β-lactamase (CTXM 8)
- CefoTaXime-M-β-lactamase (CTXM 9)
- CefoTaXime-M-β-lactamase (CTXM 25)
- New Delhi metallo-β-lactamase (NDM)
- Verona integron-encoded metallo-β-lactamase (VIM)
- Verona integron-encoded metallo-β-lactamase (VIM 7)
- Verona integron-encoded metallo-β-lactamase (VIM 13)
- Cephamycinase (CMY 1)
- Cephamycinase (CMY 2)
- Cefoxitin-Hydrolyzing Class C-β-lactamase (FOX)
- Oxacillinase Group (OXA 1)
- Oxacillinase Group (OXA 2)
- Oxacillinase Group (OXA 48)
- Methicillin Resistence (mecA)
- Sulfonamide-Resistant isolate (Sul 1)
- Sulfonamide-Resistant isolate (Sul 2)
- Sulfonamide-Resistant isolate (Sul 3)
- Erythromycin Resistance Gene (ermB)
- Plasmid-Mediated Quinolone Resistance Determinant (qnrA 1)
- Plasmid-Mediated Quinolone Resistance Determinant (qnrB 1)
- Plasmid-Mediated Quinolone Resistance Determinant (qnrB 5)
- Plasmid-Mediated Quinolone Resistance Determinant (qnrS)
- Vancomycin Resistance (Van A)
- Vancomycin Resistance (Van B)
- Vancomycin Resistance (VanC 1)
- Vancomycin Resistance (VanC 2-4)
- Tracking and reporting of microbes and resistance genes
- Important microbiology infection rates and percentages
- Drug expertise and dosage recommendations
- Plans of action, protocols, and guidelines
- Infection control measures
- Continuing education
Molecular results, including antibiotic resistance, can provide clinicians with the information needed to prescribe the right treatment plan the first time.